Biofrontera Inc. (BFRIW) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Woburn, DE, United States. Der aktuelle CEO ist Hermann Luebbert.
BFRIW hat IPO-Datum 2021-10-29, 92 Vollzeitbeschäftigte, gelistet an der NASDAQ Capital Marke, eine Marktkapitalisierung von $349.45K.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
